about
New Class of Inhibitors of Amyloid-beta Fibril Formation. IMPLICATIONS FOR THE MECHANISM OF PATHOGENESIS IN ALZHEIMER'S DISEASEProfile of gantenerumab and its potential in the treatment of Alzheimer's diseaseStructure-based design of non-natural amino-acid inhibitors of amyloid fibril formationCompounds that bind APP and inhibit Abeta processing in vitro suggest a novel approach to Alzheimer disease therapeuticsClioquinol and other hydroxyquinoline derivatives inhibit Abeta(1-42) oligomer assembly.A peptide that binds specifically to the β-amyloid of Alzheimer's disease: selection and assessment of anti-β-amyloid neurotoxic effects.Peptides for therapy and diagnosis of Alzheimer's disease.Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesisControlling amyloid growth in multiple dimensions.The molecular mechanisms of the anti-amyloid effects of phenols.Structure-based discovery of fiber-binding compounds that reduce the cytotoxicity of amyloid beta.Chemical chaperone and inhibitor discovery: potential treatments for protein conformational diseases.The development of new therapeutics for Alzheimer's disease.The nature of amyloid-like glucagon fibrilsA survey of peptides with effective therapeutic potential in Alzheimer's disease rodent models or in human clinical studies.Targeting synaptic dysfunction in Alzheimer's disease therapy.Therapeutic strategies against protein misfolding in neurodegenerative diseases.Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future.Aβ oligomer toxicity inhibitor protects memory in models of synaptic toxicity.Detecting hidden sequence propensity for amyloid fibril formation.Inhibiting and reversing amyloid-β peptide (1-40) fibril formation with gramicidin S and engineered analogues.Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro.
P2860
Q22248067-4BBFE231-B13E-4296-B98D-04500EB5A547Q27027675-4FAD90C2-88E5-4FEB-8DB0-6C63045C79B8Q27670453-E4F345F6-BDAF-44A1-A1ED-F702FB18BD6CQ28237347-E9AD21DC-0BE6-456E-98E1-FB97CA11D684Q33491897-BD0E78D3-CBFC-4FCF-885B-87B1C3713FB1Q34079353-970CBEEA-5F89-4780-9153-62B31F64EB60Q34124260-08FEEADF-8574-43C1-90DB-1250EC1654F7Q34478940-527F59E3-D9AD-4FE4-8A8B-3E97E1EFA102Q36654594-C97BCDEA-0BBE-4175-B02F-5E2F6511B9B4Q36799375-FCB5B07B-35FF-457E-8E33-E8202E886225Q37019530-BCB128F0-1FFB-45EE-A128-7597ED7A598EQ37369854-F3D25F2B-2194-4029-91CD-D1D597E3DFB4Q37784685-8A9D4E3C-07EB-4036-A2D1-EF59EBFDE270Q37815570-C5D1E843-485A-4E31-83A1-A8CF335A3A43Q37981246-7BEB0BB7-8897-4500-82E5-B1413E30F4B2Q38036916-5582CF2A-173A-4A91-9427-5DDE5A1FB535Q38088318-64CDE9E3-AA6A-401E-8716-E20948651CBEQ38299414-D2B63409-B5E4-4A8B-BABF-851F06AF8418Q39293031-A3860B07-E59B-47D4-A92E-C8A99BD07B28Q41882613-048EC433-7CBC-410A-8B20-8B3921D4B8F3Q46864842-F3703563-C67A-4CE0-B8AB-AA22D01FB7CCQ53381705-9353239F-E680-48BE-839C-E928D31F9B0E
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Peptide inhibitors of beta amyloid aggregation.
@ast
Peptide inhibitors of beta amyloid aggregation.
@en
Peptide inhibitors of beta amyloid aggregation.
@nl
type
label
Peptide inhibitors of beta amyloid aggregation.
@ast
Peptide inhibitors of beta amyloid aggregation.
@en
Peptide inhibitors of beta amyloid aggregation.
@nl
prefLabel
Peptide inhibitors of beta amyloid aggregation.
@ast
Peptide inhibitors of beta amyloid aggregation.
@en
Peptide inhibitors of beta amyloid aggregation.
@nl
P356
P1476
Peptide inhibitors of beta amyloid aggregation.
@en
P2093
Mark A Findeis
P304
P356
10.2174/1568026024607508
P577
2002-04-01T00:00:00Z